Mesentech is developing innovative drugs that can selectively distribute to musculoskeletal tissue. These drugs carry payloads such as small-molecule hormones or anti-cancer agents.
Mesentech was founded by Dr. Robert Young, who led teams that discovered SingulAir, Vioxx, Arcoxia, ondanacatib, among others while leading medicinal chemistry at Merck. MES1022 is a clinical stage compound that regenerates muscle and bone with selective distribution to musculoskeletal compartments. It shows promise in treatment of muscle atrophy in muscular dystrophies. MES3015 is an anti cancer agent that selectively distributes to bone.
Founders
Bob Young
Pharmaceutical Chemist specializing in drugs for bone formation
Michael Underhill
Stem Cell Biologist researching the mechanisms behind molecular and cellular interaction
Fabio Rossi
Cellular & Molecular Biologist in tissue regeneration and mesenchymal stem cells
Pieter Cullis
Nano-particle Biochemist specializing in drug delivery
Our Partners